Italia markets closed

Galapagos NV (0JXZ.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
55,28-0,37 (-0,67%)
Alla chiusura: 08:04AM BST
Schermo intero
Chiusura precedente55,65
DenaroN/D x N/D
DomandaN/D x N/D
Min-Max giorno55,22 - 55,28
Intervallo di 52 settimane32,26 - 55,28
Media Volume21.615
Beta (mensile su 5 anni)0,06
Rapporto PE (ttm)N/D
EPS (ttm)N/D
Prossima data utili01 ago 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Galapagos appoints Simon Sturge to its Board of Directors

    Mechelen, Belgium; 19 September 2023, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that during its meeting of 19 September 2023, the Board of Directors appointed Mr. Simon Sturge as Non-Executive Independent Director by way of cooptation. Mr. Sturge replaces Dr. Mary Kerr who stepped down on 18 September 2023. Mr. Sturge brings over 40 years of international biotech and pharma experience with leadership positions at Merck KGaA and Boehringer Ingelheim. He held CEO roles at s

  • GlobeNewswire

    Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus

    GLPG3667 is an investigational, novel, oral, reversible, and selective tyrosine kinase 2 (TYK2) inhibitor GLPG3667 is currently in development for the treatment of inflammatory and auto-immune diseases and is in Phase 2 for dermatomyositis Mechelen, Belgium; 28 August 2023, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the first patient was randomized in GALACELA, a Phase 2 systemic lupus erythematosus (SLE) trial with GLPG3667. The GALACELA Phase 2 trial (NCT05856448) i

  • GlobeNewswire

    Galapagos announces first half-year 2023 financial results

    Half-year 2023 key financials Group revenues of €328.8 million Jyseleca® net sales of €54.3 million Cash and current financial investments of €3.9 billion on 30 June 2023 Full year 2023 net sales guidance for Jyseleca® lowered to €100-€120 million – 2023 cash burn guidance of €380-€420 million reiteratedOncology pipeline update – continued progress with point-of-care manufactured CAR-T candidates in hemato-oncology, including approval of the clinical trial application in Europe for BCMA CAR-T ca